Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma

Gould, Hannah J.; Mackay, Graham; Karagiannis, Sophia N.; O’Toole, Carol; Marsh, Philip; Daniel, Barbara; Coney, Leslie R.; Zurawski, Vincent R.; Joseph, M.; Capron, Moníque; Gilbert, Michel; Murphy, Gëorge F.; Korngold, Robert

doi:10.1002/(sici)1521-4141(199911)29:11<3527::aid-immu3527>3.3.co;2-x

Cited by 33 publications

(74 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present work has confirmed the previous findings that MOv18 IgE is effective in IgE ADCC against ovarian tumor cells in vivo and indeed more effective than MOv18 IgG1 [16]. We also demonstrate for the first time that human monocytes expressing the high-affinity IgE receptor, Fc 4 RI, are active in IgE ADCC.…”

Section: Introductionsupporting

confidence: 91%

“…2B). The half-life of free serum IgG in both mouse and human is longer than that of IgE (20 vs. 2-3 days), but the half-life of IgE bound to cell receptors is longer than that of IgG (20 h vs. seconds for cells in suspension and 14 days vs. 2-3 days in tissues [16]). The extended lifetime of receptor-bound IgE may allow cells to locate and kill tumor cells in solid tissues more effectively than IgG.…”

Section: Discussionmentioning

confidence: 98%

“…In the earlier study we used IGROV1 cells injected s.c. into SCID mice [16], whereas in the present work we have used HUA cells injected i.p. into nude mice.…”

Section: Discussionmentioning

confidence: 99%

“…4). We previously observed that IGROV1 cells trigger IgE-antibody-sensitized basophil degranulation, as measured by histamine release [16], but the effect on tumor growth remains to be investigated.…”

Section: Discussionmentioning

confidence: 99%

“…To compare IgE and IgG1 antibodies in a "human" effector system we have used xenografts of human ovarian tumors and human PBMC in SCID mice [16,17] and nude mice (the present work). We used chimeric MOv18 IgE and IgG1 antibodies against the folic acid receptor, which is overexpressed on about 80% of serous nonmucinous ovarian adenocarcinomas [18,19].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Activity of human monocytes in IgE antibody‐dependent surveillance and killing of ovarian tumor cells

et al. 2003

View full text Add to dashboard Cite

We have previously shown that a chimeric IgE antibody against the folic acid receptor (MOv18 IgE) inhibits tumor growth in a SCID mouse model of ovarian carcinoma. MOv18 IgE gave greater protection than the corresponding chimeric MOv18 IgG1. We have now confirmed these effects in a nude-mouse model of ovarian carcinoma and have demonstrated for the first time that human monocytes are active in IgE antibody-dependent cell-mediated cytotoxicity. Injection of tumor-bearing mice with PBMC and MOv18 IgE led to infiltration of monocytes into the tumors and prolonged survival of the mice. Incubation of PBMC or purified monocytes and MOv18 IgE with ovarian tumor cells in vitro resulted in tumor cell killing proportional to the expression of unoccupied Fc 4 RI on monocytes. We observed phagocytosis of tumor cells by the monocytes in vitro. Our results suggest that tumor-specific IgE antibodies may be exploited for immunotherapy of cancer.

show abstract

Section: Introductionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 98%

“…In the earlier study we used IGROV1 cells injected s.c. into SCID mice [16], whereas in the present work we have used HUA cells injected i.p. into nude mice.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Activity of human monocytes in IgE antibody‐dependent surveillance and killing of ovarian tumor cells

et al. 2003

View full text Add to dashboard Cite

show abstract

Development of downstream processing to minimize beta‐glucan impurities in GMP‐manufactured therapeutic antibodies

Vigor

Emerson

Scott

et al. 2016

Biotechnology Progress

Self Cite

View full text Add to dashboard Cite

The presence of impurities or contaminants in biological products such as monoclonal antibodies (mAb) could affect efficacy or cause adverse reactions in patients. ICH guidelines (Q6A and Q6B) are in place to regulate the level of impurities within clinical drug products. An impurity less often reported and, therefore, lacking regulatory guideline is beta‐glucan. Beta‐glucans are polysaccharides of d‐glucose monomers linked by (1‐3) beta‐glycosidic bonds, and are produced by prokaryotic and eukaryotic organisms, including plants. They may enter manufacturing processes via raw materials such as cellulose‐based membrane filters or sucrose. Here we report the detection of beta‐glucan contamination of a monoclonal IgE antibody (MOv18), manufactured in our facility for a first‐in‐human, first‐in‐class clinical trial in patients with cancer. Since beta‐glucans have potential immunostimulatory properties and can cause symptomatic infusion reactions, it was of paramount importance to identify the source of beta‐glucans in our product and to reduce the levels to clinically insignificant concentrations. We identified beta‐glucans in sucrose within the formulation buffer and within the housing storage buffer of the virus removal filter. We also detected low level beta‐glucan contamination in two of four commercially available antibodies used in oncology. Both formulation buffers contained sucrose. We managed to reduce levels of beta‐glucan in our product 10‐fold, by screening all sucrose raw material, filtering the sucrose by Posidyne® membrane filtration, and by incorporating extra wash steps when preparing the virus removal filter. The beta‐glucan levels now lie within a range that is unlikely to cause clinically significant immunological effects. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 32:1494–1502, 2016

show abstract

An overview of the association between allergy and cancer

Turner

Chen

Krewski

et al. 2006

Intl Journal of Cancer

134

126

View full text Add to dashboard Cite

Numerous epidemiological studies have evaluated some aspect of the association between a history of allergy and cancer occurrence. In this article, an overview of the epidemiological evidence is presented with a discussion of a number of methodological issues important in this area of study. Literature searches were conducted using the MEDLINE database from 1966 through to August 2005 to identify articles that explored a personal history of allergic disorders as a risk factor for cancer. Although it is difficult to draw conclusions between allergy and cancer at many sites because of insufficient evidence or a lack of consistency both within and among studies completed to date, strong inverse associations have been reported for pancreatic cancer and glioma, whereas lung cancer was positively associated with asthma. Additional studies are needed to confirm these finding and to address the limitations of previous studies, including the validity and reliability of exposure measures and control for confounding. Further, large prospective studies using cancer incidence would be particularly useful, including studies using biological markers of allergic status to reduce potential misclassification and to confirm the results of previous studies based on self-report. There is also a need for further basic research to clarify a potential mechanism, should an association exist. ' 2006 Wiley-Liss, Inc.Key words: allergy; neoplasms; epidemiology; etiology Cancer is a major threat to population health and is currently the second leading cause of death in Canada and the United States. 1,2 Cancer researchers have attempted to describe a role for various biological, lifestyle, and environmental factors in cancer development, including a potentially important role for the immune system. [3][4][5] The concept of immune surveillance, first proposed almost a century ago, 6,7 suggests that the immune system is continuously searching for and destroying tumor cells as they arise. Although historically controversial, recent scientific advancements have led to renewed interest in the immune surveillance theory. 3,[7][8][9] It has been suggested that those with a history of allergy, in particular atopic disorders, may possess an enhanced capacity for immune surveillance. [10][11][12][13] Although it has been commonly assumed that the atopic immune response offers little benefit to individuals, recently, it has been argued that it may offer a valuable evolutionary advantage. 14,15 This immune response may also be related to cancer development.Numerous epidemiological studies have evaluated some aspect of the association between a history of allergy and cancer occurrence. In this article, we provide an overview of the epidemiological evidence and discuss a number of methodological issues important in this area of study. A critical assessment of the literature in this area is important to clarify previous conflicting reports and to determine future research directions. MethodsLiterature searches were conducted using the MEDLINE database fro...

show abstract

Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma

Cited by 33 publications

References 0 publications

Activity of human monocytes in IgE antibody‐dependent surveillance and killing of ovarian tumor cells

Activity of human monocytes in IgE antibody‐dependent surveillance and killing of ovarian tumor cells

Development of downstream processing to minimize beta‐glucan impurities in GMP‐manufactured therapeutic antibodies

An overview of the association between allergy and cancer

Contact Info

Product

Resources

About